Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REGN

Regeneron Pharmaceuticals, Inc

Oct 27 • 03:25PM ET

582.56

+4.61 0.80 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ IVV SPY VTV XLV IBB JEPI COWZ

Scroll to Statements

Index	NDX, S&P 500	P/E	14.68	EPS (ttm)	39.69	Insider Own	3.63%	Shs Outstand	104.60M	Perf Week	1.00%
Market Cap	61.74B	Forward P/E	14.15	EPS next Y	41.17	Insider Trans	0.00%	Shs Float	102.14M	Perf Month	3.31%
Enterprise Value	56.96B	PEG	6.47	EPS next Q	9.65	Inst Own	85.75%	Short Float	2.87%	Perf Quarter	4.37%
Income	4.46B	P/S	4.34	EPS this Y	-12.26%	Inst Trans	-3.33%	Short Ratio	2.86	Perf Half Y	-4.63%
Sales	14.21B	P/B	2.07	EPS next Y	2.86%	ROA	12.00%	Short Interest	2.93M	Perf YTD	-18.22%
Book/sh	281.38	P/C	8.24	EPS next 5Y	2.27%	ROE	15.34%	52W High	943.83 -38.28%	Perf Year	-38.12%
Cash/sh	70.66	P/FCF	16.02	EPS past 3/5Y	-18.94% 15.74%	ROIC	13.66%	52W Low	476.49 22.26%	Perf 3Y	-17.47%
Dividend Est.	2.98 (0.51%)	EV/EBITDA	12.75	Sales past 3/5Y	-4.04% 16.71%	Gross Margin	81.98%	Volatility	1.60% 3.09%	Perf 5Y	1.03%
Dividend TTM	2.64 (0.45%)	EV/Sales	4.01	EPS Y/Y TTM	3.58%	Oper. Margin	27.83%	ATR (14)	15.83	Perf 10Y	11.27%
Dividend Ex-Date	Aug 18, 2025	Quick Ratio	3.72	Sales Y/Y TTM	5.38%	Profit Margin	31.37%	RSI (14)	53.37	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	4.60	EPS Q/Q	3.24%	SMA20	0.79%	Beta	0.30	Target Price	728.91
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	3.62%	SMA50	1.08%	Rel Volume	0.75	Prev Close	577.95
Employees	15106	LT Debt/Eq	0.09	Earnings	Oct 28 BMO	SMA200	-2.46%	Avg Volume	1.02M	Price	582.56
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	52.89% 11.78%	Trades		Volume	699,472	Change	0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976

Show Previous Ratings

Oct-26-25 11:13PM	Regeneron Earnings: What To Look For From REGN (StockStory)
07:25AM	European Medicines Agency Adopts a Positive Opinion on ?Regeneron's (REGN) Libtayo (Insider Monkey)
Oct-24-25 07:03PM	Analyst Report: Sanofi (Morningstar Research)
04:12PM	Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue (Investor's Business Daily)
03:19PM	Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week (The Wall Street Journal)
01:14PM	Loading…
01:14PM	Long Leaf Partners Fund's Comment on Regeneron (REGN) (Insider Monkey)
10:01AM	Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline (Zacks)
09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
02:55AM	Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance (The Wall Street Journal)
Oct-23-25 09:15AM	Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS (Zacks)
09:05AM	RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised (Zacks)
Oct-21-25 10:00AM	Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline (Zacks)
Oct-20-25 09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 04:21PM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily)
07:30AM	Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation (GlobeNewswire)
02:54AM	Loading…
Oct-16-25 02:54AM	REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised) (Zacks)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
07:00AM	Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers (GlobeNewswire)
Oct-14-25 10:49AM	Regenerons Q3 2025 Earnings: What to Expect (Barchart)
10:00AM	2 Stocks Down 17% and 21% to Buy Right Now (Motley Fool)
Oct-13-25 10:02AM	REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Zacks)
09:44AM	Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge (Insider Monkey)
09:41AM	Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage) (Investor's Business Daily)
Oct-12-25 10:18AM	DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss (GlobeNewswire)
06:18AM	Regeneron, with game-changing new data, to seek approval of hearing loss gene therapy (BioPharma Dive)
Oct-09-25 04:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
09:15AM	Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo (Zacks)
07:23AM	Regeneron, needing a turnaround, gains new use for cancer drug (BioPharma Dive)
Oct-08-25 02:31PM	Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation (GlobeNewswire)
Oct-07-25 11:49AM	11 Cheap Stocks for a Market That's Too Expensive (Barrons.com)
04:59PM	Loading…
Oct-06-25 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-02-25 04:55PM	Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management (Insider Monkey)
09:45AM	Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough (Insider Monkey)
Oct-01-25 08:10PM	Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials (Insider Monkey) +6.70%
02:16AM	Regeneron's Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5 (Insider Monkey)
Sep-30-25 04:05PM	Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 (GlobeNewswire)
07:30AM	2 Beaten-Down Stocks to Buy and Hold for a Decade (Motley Fool)
Sep-29-25 02:53PM	Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease (Insider Monkey)
10:43AM	Here's Why Regeneron Pharmaceuticals (REGN) Fell in Q2 (Insider Monkey)
08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
06:02AM	Regenerons Evkeeza gains FDA approval for young HoFH patients (Pharmaceutical Technology)
12:36AM	1 Healthcare Stock with Exciting Potential and 2 We Ignore (StockStory)
Sep-26-25 07:00AM	Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol (GlobeNewswire)
Sep-25-25 04:51PM	Why Regeneron (REGN) Shares Are Falling Today (StockStory)
Sep-24-25 01:57AM	Regeneron's Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide (Insider Monkey)
Sep-23-25 03:26PM	Why Regeneron (REGN) Stock Is Down Today (StockStory)
09:45AM	Stock Market Today: Dow Up Ahead Of Powell Speech; Nvidia At Buy Point (Live Coverage) (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
Sep-22-25 12:03PM	SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU (Zacks)
09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)
12:29AM	Dupixent (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion (GlobeNewswire)
Sep-19-25 01:17PM	Can Regeneron Change The Paradigm In Multiple Myeloma - And Undercut J&J? (Investor's Business Daily)
12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
07:06AM	Arvinas reboots, cuts more staff; Porges joins Lazard (BioPharma Dive)
07:00AM	Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks (GlobeNewswire)
Sep-18-25 12:02AM	3 Reasons to Sell REGN and 1 Stock to Buy Instead (StockStory)
Sep-17-25 02:27PM	Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies (Insider Monkey)
09:30AM	Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD (GlobeNewswire)
07:00AM	Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation (GlobeNewswire)
Sep-16-25 12:30PM	Kymera initiated at Outperform on potential of lead skin drug (Investing.com)
12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
11:42AM	Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial (Insider Monkey)
Sep-15-25 09:53AM	REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock? (Zacks)
08:15AM	BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN) (Insider Monkey)
Sep-14-25 01:17AM	BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT (Insider Monkey)
Sep-12-25 08:33AM	Maias NSCLC immunotherapy secures Phase II efficacy win (Clinical Trials Arena)
Sep-11-25 12:55PM	Phase III success for Regeneron signals pozelimab and cemdisirans entry into MG market (Clinical Trials Arena)
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 07:33AM	Kriya, Odyssey secure megarounds; Amgen boosts R&D leadership (BioPharma Dive)
04:00AM	Pharmas new boomtown? Why drugmakers are setting up shop in a small Swiss city. (Pharma Voice)
Sep-09-25 03:10PM	Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy (Benzinga)
12:38PM	Regenerons cat and birch allergy mAbs score in Phase III trials (Clinical Trials Arena)
12:28PM	Health Care Roundup: Market Talk (The Wall Street Journal)
07:00AM	Libtayo (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer (GlobeNewswire)
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks)
06:30AM	Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies (GlobeNewswire)
Sep-07-25 09:15AM	2 Beaten-Down Stocks to Buy on the Dip (Motley Fool)
Sep-05-25 10:11AM	RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress (Zacks)
Sep-04-25 04:05PM	Regeneron Announces Updated Presentation Time for Upcoming Investor Conference (GlobeNewswire)
01:32PM	Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory (Insider Monkey)
10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)
09:10AM	Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar' (Investor's Business Daily)
Sep-03-25 11:32PM	Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best (StockStory)
11:30AM	Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report? (Zacks)
10:07AM	MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline (Zacks)
02:58AM	How Is Regenerons Stock Performance Compared to Other Pharma Stocks? (Barchart)
Sep-02-25 11:12AM	Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT (Insider Monkey)
Aug-29-25 04:51AM	Regeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks (Insider Monkey)
Aug-28-25 05:00AM	FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)'s Linvoseltamab for Multiple Myeloma (Insider Monkey)
Aug-27-25 12:06PM	Regeneron tees up myasthenia gravis drug approval after Phase III victory (Clinical Trials Arena)
09:15AM	What Are Wall Street Analysts Target Price for Regeneron Pharmaceuticals Stock? (Barchart)
Aug-26-25 11:17AM	Immuneering Stock Rises 21.7% on Supply Agreement With LLY (Zacks)
10:50AM	Stock Market Today: Stocks rise despite Trump threats against Fed, tech regulation (TheStreet)
08:39AM	The FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN) (Insider Monkey)
07:54AM	J&J earmarks $2B for Fujifilms North Carolina facility (Manufacturing Dive)
07:00AM	Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis (GlobeNewswire)
Aug-25-25 01:59PM	FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles (Benzinga)
Aug-24-25 08:45AM	2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts (Motley Fool)
Aug-22-25 05:57AM	The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk (Zacks)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SING GEORGE L	Director	Dec 31 '24	Option Exercise	413.33	3,338	1,379,696	29,610	Jan 03 04:02 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Nov 05 04:23 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Sale	844.61	1,000	844,610	12,931	Nov 05 04:23 PM
MARION E MCCOURT	Officer	Nov 01 '24	Proposed Sale	844.61	1,000	844,610		Nov 01 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience